News

Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement
Positive Lexeo Therapeutics, Inc. interim data from SUNRISE-FA study highlights LX2006's potential for Friedreich's Ataxia.
Woman's World on MSN3h
3 Heart Disease Risk Factors Women Shouldn't Ignore, Yale Doctor Says
When it comes to risk factors for heart disease, some are simply out of our control (like a family history of heart trouble, ...
Canadian Medical Association Journal11h
Diabetic ketoacidosis induced by a sodium–glucose cotransporter-2 inhibitor in a 28-year-old man without known diabetes
Key points A 28-year-old man with cocaine and alcohol use disorders presented to the emergency department with a 2-month history of worsening shortness of breath, orthopnea, and fatigue. His medical ...
The Manila Times11h
Study Shows Large Improvements in Long COVID Symptoms and Return to Work
While estimates of those still coping with Long COVID vary, some 20 million Americans have been diagnosed with Long Covid, ...
pharmaphorum23h
Capricor files cell therapy for DMD cardiomyopathy with FDA
Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will become the first approved treatment for cardiomyopathy associated with ...